4B Technologies was selected into the list of "2023 China Biomedical Industry Front-runners 100”

Release date: Oct  20,  2023

Recently, 4B Biotechnologies was selected for the "2023 China Biomedical Industry  Front-runners 100" list. The list is jointly published by Shanghai Biomedical Industry Promotion Center, PricewaterhouseCoopers, Shanghai STVC Group, Yiyun Technology, and First Financial Union.

The selection event for China's biomedical industry leaders aims to focus on non-publicly-listed biotech companies, taking into account their valuation rankings, growth and innovation capabilities. Through six dimensions - strategy, product, competition, business, team, and value - and more than 50 indicators, a group of cutting-edge technology pioneers and leaders driving industry transformation in the field of biomedicine are selected.


Previous : First-in-Class Monoclonal Antibody 4B03-04 Got Approval in Australia for Clinical Study Next : 4B Technologies was selected into the final list of KPMG China Future Sector 50 Ranking Series—Biotech